What Researchers Did
This clinical guideline reviewed the emergence, characteristics, and management of bisphosphonate-associated osteonecrosis of the jaws (ONJ).
What They Found
Bisphosphonate-associated ONJ was first reported in 2003, with over 2,500 cases accumulating worldwide by 2007. This condition often occurs after dental treatments and does not respond to conventional therapies, leading to recommendations for empirical conservative management.
What This Means for Canadian Patients
Canadian patients receiving bisphosphonates, especially for cancer, should be aware of the risk of ONJ, particularly following dental procedures. It is crucial for these patients to discuss their medication history with their dentists and for healthcare providers to collaborate on prevention and management strategies.
Canadian Relevance
This study has no direct Canadian connection as it is a clinical guideline from Japan, but the medical principles regarding bisphosphonate-associated ONJ are globally relevant.
Study Limitations
As a clinical guideline, this study synthesizes existing knowledge but highlights the ongoing challenge of establishing effective therapies for ONJ.